CHENGDU SHENGNUO BIOTEC CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.27 CNY | +2.43% |
|
+4.70% | +0.25% |
| Sales 2024 * | 570M 78.68M | Sales 2025 * | 800M 110M | Capitalization | 3.17B 437M |
|---|---|---|---|---|---|
| Net income 2024 * | 99M 13.67M | Net income 2025 * | 140M 19.33M | EV / Sales 2024 * | 5.55 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.96 x |
| P/E ratio 2024 * |
31.8
x | P/E ratio 2025 * |
22.6
x | Employees | 879 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.94% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.43% | ||
| 1 week | +4.70% | ||
| Current month | -3.52% | ||
| 1 month | -8.81% | ||
| 3 months | +31.18% | ||
| 6 months | +1.00% | ||
| Current year | +0.25% |
1 week
25.57
28.70
1 month
25.5730.90
Current year
16.4632.30
1 year
16.4635.38
3 years
14.7657.86
5 years
14.7657.86
10 years
14.7657.86
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Jun Wen
CEO | Chief Executive Officer | 58 | 01-07-22 |
Li Wu
DFI | Director of Finance/CFO | 50 | 14-09-30 |
Jing Meng Zhang
ADM | Chief Administrative Officer | 43 | 06-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Qiong Tang
BRD | Director/Board Member | 61 | 18-12-11 |
Yong Jun Wen
CEO | Chief Executive Officer | 58 | 01-07-22 |
Xiao Li Wang
BRD | Director/Board Member | 54 | 03-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 28.27 | +2.43% | 1 013 570 |
| 24-04-24 | 27.6 | +0.36% | 1,171,990 |
| 24-04-23 | 27.5 | +2.96% | 2,401,599 |
| 24-04-22 | 26.71 | +1.83% | 1,200,164 |
| 24-04-19 | 26.23 | +0.58% | 1,032,583 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes
Cheng Du Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's products target areas including immunology, digestive tract, antivirus, gynecology, diabetes, cardio-cerebrovascular, rare diseases, orthopedics and other fields. The Company is also engaged in customized peptide production services for customers, customized production services for peptide APIs and preparations, and technology transfer services for peptide drug production. The Company also provides small-molecule chemical drug Levosimendan preparations on behalf of processing, Levosimendan bulk drug production and export sales business.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
27.6
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.25% | 427M | |
| +18.59% | 22.25B | |
| +13.82% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -8.24% | 4.51B |
- Stock Market
- Equities
- 688117 Stock
